Investing.com - Financial Markets Worldwide

Central Pharmaceutical CPC1 JSC (DP1)

Hanoi
Currency in VND
37,200
0(0.00%)
Closed·

DP1 Financial Summary

Key Ratios

P/E Ratio0
Price/Book0
Debt / Equity78.43%
Return on Equity24.44%
Dividend Yield0.00%
EBITDA146.10B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2012
01/01
2012
31/12
2013
31/12
2014
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa2,060,384.792,182,419.982,159,464.062,158,359.152,025,737.35
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa279,304.74248,597.29293,720.49342,594.47311,125.92
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa88,768.3468,047.4111,506.36175,384137,670.02
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa41,458.8344,992.1350,487.99102,952.58113,758.6
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa1,278,567.711,131,6021,159,932.451,285,110.441,393,197.49
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa1,016,201.16867,484.39888,590.02827,312.03881,667.35
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa262,366.54264,117.61271,342.43457,798.42511,530.14
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa98,267.1664,938.54156,252.73-139,112.867,160.5
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa110,940.674,069.05153,599.6-21,711.4314,077.8
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-9,609.89-1,134.32-11,045.92-902.333,483.31
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-107,066.28-74,336.93-134,216.6921,702.04-35,962.02
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-5,699.73-1,431.88,355.62-890.99-18,391.06
* In Millions of VND (except for per share items)

Earnings

Latest Release
Jul 21, 2025
EPS / Forecast
1,070.00 / --
Revenue / Forecast
547.56B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Central Pharma CPC1's earnings for the latest quarter?

The Central Pharma CPC1 EPS (TTM) is 4,893.12. Central Pharma CPC1 reported sales of 547,564.39, net income of 22,462.61, and EPS of 1,070.00 for the latest quarter.

What was Central Pharma CPC1's net income for the latest quarter?

Central Pharma CPC1's net income for the latest quarter was 22,462.61.

How did Central Pharma CPC1's performance compare year-over-year in the latest quarter?

The company's revenue moved from 516,344.10 in the previous quarter to 547,564.39 in the latest quarter, and net income moved from 26,810.24 to 22,462.61 compared to the previous quarter.

What is Central Pharma CPC1's net profit margin on a TTM basis?

Central Pharma CPC1's trailing twelve months (TTM) net profit margin is 5.62%.

How does Central Pharma CPC1's debt to equity ratio compare to industry standards?

Central Pharma CPC1's total debt-to-equity ratio is 78.43%.

What is Central Pharma CPC1's return on investment on a TTM basis?

Central Pharma CPC1's trailing twelve months (TTM) return on investment (ROI) is 24.44%.

Did Central Pharma CPC1 gain or lose cash last quarter?

In the latest quarter, Central Pharma CPC1's net change in cash was 24,226.89 million.

What were Central Pharma CPC1's total assets and liabilities in the latest quarter?

As of the latest quarter, Central Pharma CPC1 reported total assets of 1,514,527.62 million and total liabilities of 982,255.91 million.

How has Central Pharma CPC1's total revenue grown this year?

Central Pharma CPC1's total revenue was 516,344.10 in the previous quarter and 547,564.39 in the latest quarter.

What is Central Pharma CPC1's gross margin on a TTM basis?

Central Pharma CPC1's trailing twelve months (TTM) gross margin is 14.58%.

What was Central Pharma CPC1's revenue per share for the latest quarter?

Central Pharma CPC1's revenue per share for the latest quarter was 29,566.33.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.